Insurance Coverage for Weight Loss Drugs: A Complete Guide
Navigate insurance coverage for GLP-1 medications like Wegovy and Zepbound. Learn what Medicare, Medicaid, and private plans cover—plus strategies to reduce your out-of-pocket costs.
Medically Reviewed
Reviewed by Dr. James Chen, MD, PhD, FACE on March 5, 2026
Our medical review process ensures clinical accuracy and patient safety.
Introduction
Insurance coverage for weight loss drugs has become one of the most pressing healthcare access questions of the decade. Medications like semaglutide (Wegovy) and tirzepatide (Zepbound) can reduce body weight by 15–22% in clinical trials, yet millions of eligible Americans cannot access them due to persistent coverage gaps.
Evidence: "Among adults eligible for GLP-1 receptor agonist therapy for obesity, prescribing rates remained below 3% through 2024, with significant disparities by race, geography, and insurance type." — Kim SC, et al. JAMA. 2025. DOI: 10.1001/jama.2025.4735
At a list price of $900–$1,400 per month, out-of-pocket cost without coverage is prohibitive for most patients. Understanding which plans cover these drugs—and how to navigate the approval process—is essential before starting treatment.
Does Medicare Cover Weight Loss Drugs?
Medicare's relationship with anti-obesity medications has historically been restrictive. When Medicare Part D was established in 2003, weight loss drugs were explicitly excluded from coverage—a policy based on the limited efficacy and unfavorable safety profiles of medications available at that time.
Evidence: "The exclusion of anti-obesity medications from Medicare Part D coverage dates to legislation written before the GLP-1 receptor agonist era, and the dramatic efficacy of newer agents warrants urgent policy reconsideration." — Aggarwal M, et al. J Gen Intern Med. 2023. DOI: 10.1007/s11606-023-08416-9
What Medicare Covers Now
The landscape shifted partially in 2024 when CMS expanded coverage for semaglutide for cardiovascular risk reduction in patients with existing heart disease and obesity—but not for obesity treatment alone. The current coverage breakdown:
| Indication | Medicare Coverage |
|---|---|
| Type 2 diabetes (Ozempic, Rybelsus) | Covered under Part D |
| Cardiovascular risk reduction (Ozempic, Wegovy) | Covered since March 2024 |
| Obesity treatment only (Wegovy, Zepbound) | Not covered |
| Tirzepatide for diabetes (Mounjaro) | Covered under Part D |
| Tirzepatide for obesity only (Zepbound) | Not covered |
The TREAT and REDUCE Obesity Act, repeatedly introduced in Congress, would amend Medicare Part D to cover FDA-approved obesity drugs—but has not passed as of early 2026. However, CMS announced the BALANCE Model in December 2025: a Medicare GLP-1 payment demonstration scheduled to begin July 2026, marking a potential turning point.
Medicaid Coverage: A State-by-State Patchwork
Medicaid coverage for anti-obesity medications varies dramatically across states. Unlike coverage for diabetes or cardiovascular indications—which is federally required—coverage for obesity treatment remains optional for states.
Evidence: "As of 2022, fewer than one in five state Medicaid programs covered prescription anti-obesity medications for weight management, with substantial heterogeneity in prior authorization requirements and covered drug classes across states." — Liu YB, Rome BN. JAMA. 2024;331:1230–1231. DOI: 10.1001/jama.2024.3073
State Coverage Tiers (Early 2026)
Coverage generally falls into four tiers:
- Full coverage with prior authorization (~13 states): Cover GLP-1s for obesity. Includes California, New York, Colorado, and Massachusetts.
- Limited coverage (~8 states): Cover older anti-obesity medications (orlistat, phentermine) but not GLP-1 receptor agonists.
- Comorbidity-only coverage (~12 states): Require a qualifying comorbid condition such as type 2 diabetes or hypertension for approval.
- No obesity coverage (~17 states): Do not cover anti-obesity medications beyond diabetes indications.
Racial disparities compound these coverage gaps. Black and Hispanic adults—who face the highest rates of obesity—are disproportionately enrolled in Medicaid programs that provide no obesity drug coverage.
Evidence: "Among US adults eligible for semaglutide, 56.6% of Black adults and 55.0% of Hispanic adults met FDA criteria, yet both groups faced significantly higher rates of being uninsured or lacking a usual source of care compared to White adults." — Khan SS, et al. J Am Heart Assoc. 2022. DOI: 10.1161/JAHA.121.025545
Private Insurance Coverage
Employer-sponsored and individual market plans vary widely in their coverage of GLP-1 medications for weight loss. As of 2025, approximately 50–60% of large employers (500+ employees) offered some form of GLP-1 coverage for obesity, up from under 30% in 2021. However, coverage is being actively reassessed as pharmacy costs have surged.
Why Some Insurers Are Pulling Back
GLP-1 medications now account for more than 15% of annual pharmacy claims for over a quarter of large employers—a cost pressure driving some plans to restrict or drop obesity coverage:
- Several major Blue Cross Blue Shield plans dropped coverage of Wegovy, Zepbound, and Saxenda in 2025
- Mid-size employers have increasingly added step-therapy requirements, mandating prior failure on cheaper medications
- Annual prior authorization renewals with ongoing weight documentation are becoming standard
What Drives Prescription Access
Evidence: "Insurance type is independently associated with both anti-obesity medication prescribing and prescription fills; patients with Medicaid or Medicare have significantly lower odds of receiving these medications compared to those with commercial insurance, even after adjusting for clinical characteristics." — Gasoyan H, et al. Diabetes Obes Metab. 2024;26(5):1687–1696. DOI: 10.1111/dom.15473
Commercial plans that cover GLP-1s for obesity typically require:
- BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity (hypertension, sleep apnea, type 2 diabetes, dyslipidemia, cardiovascular disease)
- Documentation of prior lifestyle interventions (diet counseling, structured exercise program)
- Prior authorization, renewable annually
- Step therapy in some plans (documented failure on older medications)
How to Get Your Medication Covered
Step 1: Check Your Plan's Formulary
Before your appointment, call your insurer or check the online drug formulary. Ask specifically: "Does my plan cover Wegovy, Zepbound, or semaglutide for obesity treatment under any tier?"
Step 2: Work With Your Provider on Prior Authorization
Approvals require your physician to submit documentation including current BMI, weight-related comorbidities, a record of prior weight loss attempts, and clinical justification for the prescribed medication. Prepare this documentation before your appointment to streamline the process.
Step 3: Appeal a Denial
If your claim is denied, you have the legal right to appeal. The most effective appeals include:
- Peer-reviewed literature on medical necessity (the STEP and SURMOUNT trial data are particularly compelling)
- A detailed letter of medical necessity from your prescribing physician
- Documentation of comorbidities, cardiovascular risk factors, or metabolic consequences of untreated obesity
Approval rates on first appeal range from 30–50% depending on the insurer and quality of documentation.
Step 4: Manufacturer Savings Programs
Both Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) offer savings cards for commercially insured patients who do not have coverage:
| Drug | Program | Potential Savings |
|---|---|---|
| Wegovy (semaglutide 2.4 mg) | Novo Nordisk Savings Card | As low as $25/month for eligible patients |
| Zepbound (tirzepatide) | Eli Lilly Savings Card | As low as $25/month for eligible patients |
| Ozempic (semaglutide, diabetes) | Novo Nordisk | Variable |
| Mounjaro (tirzepatide, diabetes) | Eli Lilly | Variable |
These programs are for commercially insured patients only and are not valid for Medicare or Medicaid beneficiaries.
Step 5: Compounded GLP-1 Options
Several telehealth platforms offer compounded semaglutide or tirzepatide at $199–$499/month. These are not FDA-approved products, and the FDA has issued warnings about compounded GLP-1 medications citing quality control concerns. The FDA removed semaglutide from its drug shortage list in early 2025, which may further restrict compounding pharmacy access.
The Coverage Equity Problem
The coverage gap is not merely a financial issue—it represents a structural health equity crisis. Obesity disproportionately affects Black, Hispanic, and low-income Americans, the same populations most often covered by Medicaid programs that exclude obesity treatment, or by Medicare (which still bars obesity-only prescriptions).
Policy advocacy organizations including the Obesity Medicine Association, the Obesity Society, and the American Diabetes Association have called for mandatory national coverage of GLP-1 medications for obesity across all payer types. Without systemic change, the populations bearing the greatest burden of obesity-related disease will continue to receive the least access to its most effective treatments.
Key Takeaways
- Medicare does not cover GLP-1s for obesity treatment alone; cardiovascular indications are covered; the BALANCE Model demonstration begins July 2026.
- Medicaid coverage is state-dependent—only about 13 states covered GLP-1s for obesity as of early 2026.
- Private insurance coverage is expanding but inconsistent; prior authorization and step therapy are common hurdles.
- Manufacturer savings programs can reduce costs to $25/month for eligible commercially insured patients.
- Appeals succeed—30–50% approval rates when supported with documentation and a letter of medical necessity.
- Working closely with your prescribing physician and preparing thorough documentation significantly improves approval odds.
If you are preparing to start therapy, see our guide on Starting GLP-1: What to Expect for week-by-week timelines and practical side effect management.
References
Kim SC, et al. Uptake of and Disparities in Semaglutide and Tirzepatide Prescribing for Obesity in the US. JAMA. 2025. DOI: 10.1001/jama.2025.4735 PubMed
Liu YB, Rome BN. State Coverage and Reimbursement of Antiobesity Medications in Medicaid. JAMA. 2024;331:1230–1231. DOI: 10.1001/jama.2024.3073 PubMed
Gasoyan H, Pfoh ER, Schulte R, et al. Association of patient characteristics and insurance type with anti-obesity medications prescribing and fills. Diabetes Obes Metab. 2024;26(5):1687–1696. DOI: 10.1111/dom.15473 PubMed
Aggarwal M, et al. Medicare Part D Coverage of Anti-obesity Medications: A Call for Forward-Looking Policy Reform. J Gen Intern Med. 2023. DOI: 10.1007/s11606-023-08416-9 PubMed
Khan SS, et al. Racial and Ethnic Disparities in Financial Barriers Among Overweight and Obese Adults Eligible for Semaglutide in the United States. J Am Heart Assoc. 2022. DOI: 10.1161/JAHA.121.025545 PubMed
Last updated: 2026-03-05 Medical review: Dr. James Chen, MD, PhD, FACE
Tags
Written By
Emily Rodriguez
Senior Medical Writer, MPH, RD
Emily Rodriguez is a registered dietitian and public health specialist. She translates complex medical research into accessible, actionable content for patients and healthcare providers.
Medical Reviewer
Dr. James Chen
Endocrinologist, MD, PhD, FACE
Dr. James Chen is a fellowship-trained endocrinologist with expertise in diabetes, metabolism, and hormone-related weight disorders. His research on GLP-1 receptor agonists has been published in leading medical journals.
Editorial Standards
This article follows our strict editorial guidelines. All content is based on peer-reviewed research and reviewed by medical professionals. This information is for educational purposes only — always consult your healthcare provider before making medical decisions.